logo
  

Pre-market Movers: GMVD, BBAI, OBIO, IXHL, APE…

us pre market 053119 30jan23 lt

The following are some of the stocks making big moves in Monday's pre-market trading (as of 07.35 A.M. ET).

In the Green

G Medical Innovations Holdings Ltd (GMVD) is up over 78% at $5.36.
BigBear.ai Holdings, Inc. (BBAI) is up over 31% at $3.19.
AMC Entertainment Holdings, Inc. (APE) is up over 16% at $2.23.
Lucid Group, Inc. (LCID) is up over 12% at $14.43.
enCore Energy Corp. (EU) is up over 12% at $2.92.
Alliance Resource Partners, L.P. (ARLP) is up over 7% at $22.22.
WiSA Technologies, Inc. (WISA) is up over 7% at $9.88.
Can-Fite BioPharma Ltd. (CANF) is up over 7% at $4.36.
Adamas One Corp. (JEWL) is up over 7% at $2.68.
Koninklijke Philips N.V. (PHG) is up over 5% at $17.86.

In the Red

Orchestra BioMed Holdings, Inc. (OBIO) is down over 22% at $8.93.
Incannex Healthcare Limited (IXHL) is down over 16% at $2.84.
Brera Holdings PLC Class B Ordinary Shares (BREA) is down over 11% at $4.29.
Cemtrex, Inc. (CETX) is down over 7% at $5.80.
HUTCHMED (China) Limited (HCM) is down over 6% at $18.56.
Grindr Inc. (GRND) is down over 6% at $5.06.
Lufax Holding Ltd (LU) is down over 6% at $3.02.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Elon Musk's brain implant firm Neuralink said it has received approval from the U.S. Food and Drug Administration to conduct first-in-human clinical trials. In a tweet, Neuralink said, "We are excited to share that we have received the FDA's approval to launch our first-in-human clinical study! T.W. Garner Food Co. is recalling 50,688 bottles of 12 oz. Texas Pete Buffalo Wing Sauce citing undeclared soy, the U.S. Food and Drug Administration said. The agency noted that some of the bottles may contain Texas Pete Extra Mild Wing Sauce which contains soy. The recall involves Texas Pete Buffalo Wing Sauce with best used by 120623T 065239 UPC 0 75500 10011 6. The U.S. Food and Drug Administration approved Pfizer Inc's COVID-19 oral antiviral pill Paxlovid for the treatment of mild-to-moderate COVID-19 in adults. Paxlovid is the first oral treatment, and the fourth drug, approved by the agency to treat COVID-19 in adults. Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) has been approved to treat adults who are at high...
RELATED NEWS
Follow RTT